G protein-coupled receptors

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Takeda’s Investigational Compound, TAK-994, an Oral Orexin Agonist in Clinical Development for Narcolepsy Type 1 (NT1)

Retrieved on: 
Wednesday, July 28, 2021
Research, Medical Supplies, FDA, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Branches of biology, Sleep disorders, Molecular neuroscience, Neuropeptides, Neuroscience, Amphetamine, Narcolepsy, G protein-coupled receptors, Orexin, Cataplexy, Hypocretin (orexin) receptor 2, Danavorexton

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.

Key Points: 
  • Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (Takeda) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to TAK-994,1 its Phase 2 investigational oral orexin agonist, which is designed to selectively target orexin 2 receptors.
  • Individuals with narcolepsy type 1 suffer from excessive daytime sleepiness, which might mean routinely falling asleep at work or in school.
  • This designation marks a key milestone in Takedas accelerated development efforts to bring this important potential therapy to patients with NT1.
  • A Study of TAK-994 in Participants With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 [NT1] or Narcolepsy Type 2 [NT2]).

Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) Drugs In Development, 2021 Research Report Featuring CombiGene, Gila Therapeutics, Takeda Pharmaceutical, XL-protein - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Biotechnology, Pharmaceutical, Health, G protein-coupled receptors, Branches of biology, Cell biology, Neuropeptide Y receptor Y2, Neuropeptide Y, Pancreatic polypeptide receptor 1, GPCR neuropeptide receptor

The "Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5 molecules.
  • Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Neuropeptide Y receptor type 2 (Y2R) is a protein encoded by the NPY2R gene.
  • The report 'Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021' outlays comprehensive information on the Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

Somatostatin Receptor Type 4 (SSTR4) Drugs In Development, 2021 Research Report Featuring Eli Lilly and Co, GlyTech, Peptide Logic, Strongbridge Biopharma - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
General Health, Pharmaceutical, Genetics, Health, G protein-coupled receptors, Branches of biology, Somatostatin receptor, Somatostatin, Mechanism of action, Somatostatin receptor 5, Somatostatin receptor 1

The "Somatostatin Receptor Type 4 (SSTR4) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Somatostatin Receptor Type 4 (SSTR4) - Drugs In Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The latest report Somatostatin Receptor Type 4 - Drugs In Development, 2021, outlays comprehensive information on the Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Somatostatin Receptor Type 4 (SSTR4) - Somatostatin receptor type 4 is a protein encoded by the SSTR4 gene.
  • Furthermore, this report also reviews key players involved in Somatostatin Receptor Type 4 (SSTR4) targeted therapeutics development with respective active and dormant or discontinued projects.

Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

Retrieved on: 
Thursday, July 1, 2021
Branches of biology, Biology, G protein-coupled receptors, Orexin antagonist, Eisai, Orexin receptor, Insomnia, Orexin, Hong Kong Airlines, Sleep

TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Key Points: 
  • TOKYO, July 1, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Hong Kong subsidiary Eisai (Hong Kong) Co., Ltd. has launched the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  • Eisai received approval for DAYVIGO in Hong Kong on February 28, 2021, and this launch is the first for DAYVIGO in Asia outside of Japan.
  • (10)
    The anti-insomnia drug market in Hong Kong as of 2020 valued at approximately 8.4 million USD, comprising nearly 9% of the insomnia drug market in Asia (Hong Kong, India, Indonesia, Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand).
  • Sleep.

Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes

Retrieved on: 
Friday, June 25, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Organ systems, Hormones, Peptide hormones, Branches of biology, Anti-diabetic drugs, Anorectics, Diabetes, Exenatide, G protein-coupled receptors, Glucagon-like peptide-1 receptor agonist, Glucagon-like peptide-1, Glucagon

This Phase III trial is the first and only completed trial of a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in adolescents aged 1017 with T2D.

Key Points: 
  • This Phase III trial is the first and only completed trial of a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in adolescents aged 1017 with T2D.
  • James Ruggles, BYDUREON Medical Lead, said: Were greatly encouraged by these results in adolescents with type 2 diabetes.
  • We hope that, once approved, exenatide once weekly will serve as a much needed convenient treatment option for adolescent patients.
  • Consequently, once weekly injections of exenatide could fill that gap in treatment options for T2D patients in this age group.

ORION BIOTECHNOLOGY SECURES $11.5M SERIES A FINANCING

Retrieved on: 
Thursday, June 17, 2021
Branches of biology, G protein-coupled receptors, Cell biology, Biology, GPR110, GPR144

ottawa, canada, June 17, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company,today announced that it has raised $11.5M USD in a Series A financing.

Key Points: 
  • ottawa, canada, June 17, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical-stage biotechnology company,today announced that it has raised $11.5M USD in a Series A financing.
  • We believe that Orion has developed a truly innovative technology for effectively targeting G Protein-Coupled Receptors (GPCRs).
  • The investment includes conversion of a Simple Agreement for Future Equity (SAFE) as well as closing the first tranche of a Series A investment.
  • Orion Biotechnology Canada Ltd, is a clinical stage biotechnology company focused on the discovery and development of precision engineered G-Protein Coupled Receptor (GPCR) targeted therapeutics.

Global Axial Spondyloarthritis (axSpA) Market Spotlight 2021-2031: Marketed & Pipeline Dugs, Clinical Trials, Regulatory Events, Probability of Success, Disease Prevalence, Revenues - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021
Health, Pharmaceutical, Medical specialties, Clinical medicine, Medicine, Arthritis, Autoimmune diseases, Rheumatology, Ankylosing spondylitis, Axial spondyloarthritis, G protein-coupled receptors, Spondyloarthropathy, Interleukin-1 family, Prostaglandin E

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, interleukin 17, IL-17 receptor, and JAK/STAT.
  • The greatest proportion of industry-sponsored drugs in active clinical development for axSpA are in the NDA/BLA phase.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for ankylosing spondylitis, followed by AbbVie

Arena Pharmaceuticals Announces Orphan Drug Designation for Etrasimod for the Treatment of Eosinophilic Esophagitis (EoE)

Retrieved on: 
Wednesday, June 9, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, G protein-coupled receptors, Branches of biology, Medical specialties, Lipids, Sphingosine-1-phosphate, Esophagitis, S1P, Health sciences, EOE, Arena Pharmaceuticals, Medication, Etrasimod, Arena Pharmaceuticals, ETRASIMOD, ARENA PHARMACEUTICALS

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE).

Key Points: 
  • Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation status to etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of eosinophilic esophagitis (EoE).
  • Etrasimod is an investigational compound that is not approved for any use in any country.
  • ARENA Pharmaceuticals is a team with a singular purpose deliver important medicines to patients.
  • Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Retrieved on: 
Wednesday, June 9, 2021
Chemical compounds, Psychoactive drugs, Branches of biology, Hypnotics, GABAA receptor positive allosteric modulators, Pyridines, Orexin antagonist, G protein-coupled receptors, Acetamides, Lemborexant, Orexin receptor, Zolpidem

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Tectonic Therapeutic Appoints Peter McNamara, PhD Senior Vice President, Head of Research

Retrieved on: 
Thursday, May 27, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Life sciences, Biology, G protein-coupled receptors, Molecular biology, Signal transduction, Biopharmaceutical

Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.

Key Points: 
  • Tectonic Therapeutic , a pre-clinical stage biotechnology company transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies, today announced that Peter McNamara, PhD has been appointed Senior Vice President, Head of Research.
  • We welcome Peter as a key member of our leadership team at Tectonic.
  • Tectonic has the technology and the experienced team to expand and accelerate the development of GPCR-targeted therapies with biologics, said Dr. McNamara.
  • The GEODe platform that Tectonic has developed is incredibly exciting and can be utilized to develop drugs that improve patient care across a number of therapeutic areas.